Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Thilo Zander"'
Autor:
Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Enrico Derenzini, Thilo Zander, Georg Hess, Ulrich Mey, Simone Ferrero, Nicolas Mach, Carola Boccomini, Sebastian Böttcher, Michèle Voegeli, Anne Cairoli, Vanesa-Sindi Ivanova, Thomas Menter, Stefan Dirnhofer, Bernhard Scheibe, Sandra Gadient, Katrin Eckhardt, Emanuele Zucca, Christoph Driessen, Christoph Renner
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102221- (2023)
Summary: Background: The Bruton's tyrosine kinase inhibitor ibrutinib and the proteasome inhibitor bortezomib have single-agent activity, non-overlapping toxicities, and regulatory approval in mantle cell lymphoma (MCL). In vitro, their combination p
Externí odkaz:
https://doaj.org/article/2a646da2dfa940a19c0def3d5335b73c
Autor:
Alexander D. Heini, Philipp Beck, Ulrike Bacher, Katja Seipel, Thilo Zander, Michael Daskalakis, Thomas Pabst
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 6, p 2378 (2023)
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of
Externí odkaz:
https://doaj.org/article/a41db59db3ec40b391bf84638a5c3f9f
Autor:
Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst
Publikováno v:
Cancers, Vol 15, Iss 1, p 44 (2022)
In patients with relapsed/refractory Burkitt lymphoma (r/r BL), overall survival (OS) is poor, and effective therapies and evidence for the best therapy are lacking. The monoclonal antibody blinatumomab may represent a novel option. However, only lim
Externí odkaz:
https://doaj.org/article/a37e810348ec416eafc10fe46e2c8dd3
Autor:
Panagiotis Samaras, Mario Bargetzi, Daniel C. Betticher, Christoph Driessen, Michel A. Duchosal, Dominik Heim, Nicolas Ketterer, Erika Lerch, Thomas Matthes, Ulrich Mey, Thomas Pabst, Adrian Schmidt, Christian Taverna, Thilo Zander, Christoph Renner
Publikováno v:
Swiss Medical Weekly, Vol 149, Iss 1314 (2019)
This update on plasma cell myeloma has been elaborated by a Swiss expert panel as a result of the plethora of new data on the treatment of plasma cell myeloma reported recently. It adds new insights to the more extensive review that was published 3 y
Externí odkaz:
https://doaj.org/article/ccb3fc8bd12844b2b79bfe03d460b9cb
Autor:
Mario Bargetzi, Reto Baumann, Sergio Cogliatti, Pierre-Yves Dietrich, Michel André Duchosal, Jeroen S. Goede, Felicitas Hitz, Carolin Konermann, Andreas Lohri, Ulrich Mey, Urban Novak, Alexandros Papachristofilou, Frank Stenner, Christian Taverna, Thilo Zander, Christoph Renner
Publikováno v:
Swiss Medical Weekly, Vol 148, Iss 2930 (2018)
Over the last few years, there have been many changes in the management of patients with follicular lymphoma, resulting in improvements in progression-free survival and quality of life. In addition to established regimens such as radiotherapy and imm
Externí odkaz:
https://doaj.org/article/b6807e7ac682479ba2f50074b69ac893
Autor:
Panagiotis Samaras, Mario Bargetzi, Daniel Betticher, Michel Duchosal, Dominik Heim, Urs Hess, Nicolas Ketterer, Erika Lerch, Thomas Matthes, Ulrich Mey, Thomas Pabst, Christian Taverna, Thilo Zander, Christoph Renner
Publikováno v:
Swiss Medical Weekly, Vol 145, Iss 0708 (2015)
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a S
Externí odkaz:
https://doaj.org/article/6b48cbe11677433baae0ff2f570eb5af
Autor:
Magdalena Hecz, Stefan Aebi, Beat Mller, Thilo Zander, Christian Riklin, Ralph Winterhalder, Daniela Weiler, Kristin Zeidler, Veronika Blum, Philipp Niederberger, Benedetta Campana, Oliver Gautschi
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum.
Autor:
Magdalena Hecz, Stefan Aebi, Beat Mller, Thilo Zander, Christian Riklin, Ralph Winterhalder, Daniela Weiler, Kristin Zeidler, Veronika Blum, Philipp Niederberger, Benedetta Campana, Oliver Gautschi
Publikováno v:
Swiss Medical Forum ‒ Schweizerisches Medizin-Forum.
Publikováno v:
Anticancer Research. 42:1821-1832
Satraplatin is an oral platinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin. Hence, we carried out a systematic biomarker analysis to identify hematolo
Autor:
Jeanne Bohler, Ulrike Bacher, Yara Banz, Raphael Stadelmann, Michael Medinger, Thilo Zander, Thomas Pabst
Publikováno v:
Bohler, Jeanne; Bacher, Ulrike; Banz, Yara; Stadelmann, Raphael; Medinger, Michael; Zander, Thilo; Pabst, Thomas (2023). Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers, 15(1), p. 44. MDPI AG 10.3390/cancers15010044
Cancers; Volume 15; Issue 1; Pages: 44
Cancers; Volume 15; Issue 1; Pages: 44
In patients with relapsed/refractory Burkitt lymphoma (r/r BL), overall survival (OS) is poor, and effective therapies and evidence for the best therapy are lacking. The monoclonal antibody blinatumomab may represent a novel option. However, only lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68443a5b795e8fdc912137eff33a162d
https://boris.unibe.ch/176825/1/cancers-15-00044-v2.pdf
https://boris.unibe.ch/176825/1/cancers-15-00044-v2.pdf